GlassScriptPhysician profile
Pamela A Lowe
NPI 1851484620
$446,603.66
in general payments reported to CMS, 2019-2025
14 companies · $56K in 2025
The $56K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123K · 2020: $31K · 2021: $90K · 2022: $54K · 2023: $52K · 2024: $40K · 2025: $56K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $100K · Travel and Lodging: $26K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $6,125 · Entertainment: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $99,806.00 |
| Travel and Lodging | $26,308.21 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,840.00 |
| Food and Beverage | $6,125.32 |
| Entertainment | $184.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $389,882.34 | 2019-2025 | Total30, Dailies Total1, Precision 1 |
| Maculogix, INC. | $54,080.68 | 2019-2021 | |
| Coopervision INC. | $1,288.95 | 2019-2025 | Myday Contact Lens, Synergeyes Contact Lens |
| Optos, INC. | $373.73 | 2020-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Visionix USA, INC | $362.00 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $158.64 | 2019-2020 | |
| Abb Con-Cise Optical Group LLC | $119.31 | 2020-2023 | Spectacle Lenses, Contact Lens |
| Allergan, INC. | $100.92 | 2022 | |
| Sight Sciences, INC. | $75.29 | 2019 | |
| Bausch & Lomb Americas INC. | $53.72 | 2023-2024 | Infuse |
| Novartis Pharmaceuticals Corporation | $38.84 | 2020-2021 | |
| Biotissue Holdings INC. | $35.20 | 2021-2022 | |
| Topcon Healthcare, INC. | $22.81 | 2019 | |
| Lkc Technologies, INC. | $11.23 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.